Author Question: According to the product life cycle model, comparative advantage A) may move from one country to ... (Read 62 times)

abc

  • Hero Member
  • *****
  • Posts: 543
According to the product life cycle model, comparative advantage
 
  A) may move from one country to another as a product matures.
  B) always stays in the country where a product is invented.
  C) in agricultural or homogeneous manufactured goods is determined by the stage of the life cycle these products are in.
  D) Both A and C.

Question 2

Which of the following is NOT a characteristic of populist regimes?
 
  A) Nationalistic ideologies
  B) Focus on economic growth
  C) Focus on income redistribution
  D) Using economic tools to reach specific goals regarding labor, the orientation of business or the role of foreigners
  E) Focus on controlling inflation



mochi09

  • Sr. Member
  • ****
  • Posts: 335
Answer to Question 1

A

Answer to Question 2

E



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Egg cells are about the size of a grain of sand. They are formed inside of a female's ovaries before she is even born.

Did you know?

Glaucoma is a leading cause of blindness. As of yet, there is no cure. Everyone is at risk, and there may be no warning signs. It is six to eight times more common in African Americans than in whites. The best and most effective way to detect glaucoma is to receive a dilated eye examination.

Did you know?

Between 1999 and 2012, American adults with high total cholesterol decreased from 18.3% to 12.9%

Did you know?

Many people have small pouches in their colons that bulge outward through weak spots. Each pouch is called a diverticulum. About 10% of Americans older than age 40 years have diverticulosis, which, when the pouches become infected or inflamed, is called diverticulitis. The main cause of diverticular disease is a low-fiber diet.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library